NIPER Hyderabad, Boehringer Ingelheim tie up to advance pharmaceutical research
Boehringer Ingelheim India has signed two five-year MoUs with NIPER Hyderabad and Ahmedabad to strengthen pharmaceutical research, education and innovation. The collaboration will enable academic exchange, joint research initiatives and access to the company’s global open science platform opnMe.
Hyderabad: Boehringer Ingelheim India Private Limited here on Friday signed two separate MoUs with the National Institutes of Pharmaceutical Education and Research (NIPERs) at Hyderabad and Ahmedabad.
The two five-year agreements establish a framework to advance pharmaceutical research, education and innovation through joint research initiatives, academic exchange and capability-building programmes.
Under the agreement, Boehringer Ingelheim India will enable researchers and faculty at both institutes to access www.opnme.com, the company’s global open science portal. Through opnMe, the same molecules that scientists across the world use to ask new questions in early biology will now be in the hands of NIPER researchers.
NIPER – Ahmedabad and Hyderabad director Dr. Shailendra Saraf said India’s transition from a generics-led to an innovation-led pharmaceutical economy will not be made by any single institution or any single company.
Boehringer Ingelheim India managing director Meenal Gauri said after Raebareli and Hajipur, signing MoU with NIPER Ahmedabad and Hyderabad is a significant commitment.
